Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPLISAV-B for HBV vaccination in people living with HIV
NCT04193189Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2020
- Primary completion
- Aug 2024
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 10
01
Overview
A Phase 3 trial of Hepatitis B vaccine in hepatitis B (HBV), sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2020; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04193189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04193189.